Gene sequencing company Illumina (ILMN.O) said on Sunday it will divest cancer diagnostic test maker Grail (GRAL.O) after the companies battled both U.S. and European antitrust enforcers for more than two years and faced fierce opposition from activist investor Carl Icahn.
